Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Caspase Inhibition Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo.

Kopec AK, Spada AP, Contreras PC, Mackman N, Luyendyk JP.

Toxicol Sci. 2018 Apr 1;162(2):396-405. doi: 10.1093/toxsci/kfx268.

PMID:
29228388
2.

Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles.

Verma VK, Li H, Wang R, Hirsova P, Mushref M, Liu Y, Cao S, Contreras PC, Malhi H, Kamath PS, Gores GJ, Shah VH.

J Hepatol. 2016 Mar;64(3):651-60. doi: 10.1016/j.jhep.2015.11.020. Epub 2015 Nov 26.

3.

Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice.

Elbekai RH, Paranjpe MG, Contreras PC, Spada A.

Regul Toxicol Pharmacol. 2015 Jul;72(2):169-78. doi: 10.1016/j.yrtph.2015.04.007. Epub 2015 Apr 17.

PMID:
25896096
4.

Matrix metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse.

Kahraman A, Bronk SF, Cazanave S, Werneburg NW, Mott JL, Contreras PC, Gores GJ.

Hepatol Res. 2009 Aug;39(8):805-13. doi: 10.1111/j.1872-034X.2009.00541.x. Epub 2009 Jul 13.

5.

Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor.

Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC.

J Pharmacol Exp Ther. 2004 May;309(2):634-40. Epub 2004 Jan 23.

PMID:
14742742
6.

Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury.

Hoglen NC, Hirakawa BP, Fisher CD, Weeks S, Srinivasan A, Wong AM, Valentino KL, Tomaselli KJ, Bai X, Karanewsky DS, Contreras PC.

J Pharmacol Exp Ther. 2001 May;297(2):811-8.

PMID:
11303074
7.

Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine.

Engber TM, Dennis SA, Jones BE, Miller MS, Contreras PC.

Neuroscience. 1998 Dec;87(4):905-11.

PMID:
9759978
8.

Immunolocalization of the mitogen-activated protein kinases p42MAPK and JNK1, and their regulatory kinases MEK1 and MEK4, in adult rat central nervous system.

Flood DG, Finn JP, Walton KM, Dionne CA, Contreras PC, Miller MS, Bhat RV.

J Comp Neurol. 1998 Aug 31;398(3):373-92.

PMID:
9714150
9.

Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil.

Engber TM, Koury EJ, Dennis SA, Miller MS, Contreras PC, Bhat RV.

Neurosci Lett. 1998 Jan 30;241(2-3):95-8.

PMID:
9507929
10.

Region-specific targets of p42/p44MAPK signaling in rat brain.

Bhat RV, Engber TM, Finn JP, Koury EJ, Contreras PC, Miller MS, Dionne CA, Walton KM.

J Neurochem. 1998 Feb;70(2):558-71.

11.

Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice.

Contreras PC, Vaught JL, Gruner JA, Brosnan C, Steffler C, Arezzo JC, Lewis ME, Kessler JA, Apfel SC.

Brain Res. 1997 Nov 7;774(1-2):20-6.

PMID:
9452187
12.

Insulin-like growth factor-1 (IGF-1) improves both neurological motor and cognitive outcome following experimental brain injury.

Saatman KE, Contreras PC, Smith DH, Raghupathi R, McDermott KL, Fernandez SC, Sanderson KL, Voddi M, McIntosh TK.

Exp Neurol. 1997 Oct;147(2):418-27.

PMID:
9344566
13.
14.

Increased expression of IL-1beta converting enzyme in hippocampus after ischemia: selective localization in microglia.

Bhat RV, DiRocco R, Marcy VR, Flood DG, Zhu Y, Dobrzanski P, Siman R, Scott R, Contreras PC, Miller M.

J Neurosci. 1996 Jul 1;16(13):4146-54.

15.

Potential utility of rhIGF-1 in neuromuscular and/or degenerative disease.

Vaught JL, Contreras PC, Glicksman MA, Neff NT.

Ciba Found Symp. 1996;196:18-27; discussion 27-38.

PMID:
8866126
16.

Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush in mice.

Contreras PC, Steffler C, Yu E, Callison K, Stong D, Vaught JL.

J Pharmacol Exp Ther. 1995 Sep;274(3):1443-9.

PMID:
7562520
17.

Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.

Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE, Vaught JL.

Exp Neurol. 1993 Nov;124(1):73-88. Review.

PMID:
8282084
18.

rhIGF-I enhances functional recovery from sciatic crush. Time-course and dose-response study.

Contreras PC, Steffler C, Vaught JL.

Ann N Y Acad Sci. 1993 Aug 27;692:314-6. No abstract available.

PMID:
8215040
19.

The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disorders.

Lewis ME, Vaught JL, Neff NT, Grebow PE, Callison KV, Yu E, Contreras PC, Baldino F Jr.

Ann N Y Acad Sci. 1993 Aug 27;692:201-8. Review. No abstract available.

PMID:
8215023
20.

[3H]naltrindole: a potent and selective ligand for labeling delta-opioid receptors.

Contreras PC, Tam L, Drower E, Rafferty MF.

Brain Res. 1993 Feb 26;604(1-2):160-4.

PMID:
8384509
21.

Quantitative light microscopic localization of [3H]naltrindole binding sites in the rat brain.

Drower EJ, Dorn CR, Markos CS, Unnerstall JR, Rafferty MF, Contreras PC.

Brain Res. 1993 Jan 29;602(1):138-42.

PMID:
8383568
22.

Isolation and characterization of an endogenous ligand for the PCP and sigma receptors from porcine, rat, and human tissue.

Contreras PC, Gray NM, DiMaggio DA, Bremer ME, Bussom JA.

NIDA Res Monogr. 1993;133:207-22. No abstract available.

PMID:
8232514
23.

Preparation and opioid activity of analogues of the analgesic dipeptide 2,6-dimethyl-L-tyrosyl-N-(3-phenylpropyl)-D-alaninamide.

Chandrakumar NS, Yonan PK, Stapelfeld A, Savage M, Rorbacher E, Contreras PC, Hammond D.

J Med Chem. 1992 Jan 24;35(2):223-33.

PMID:
1346276
24.

BMY-14802 protects against ischemia-induced neuronal damage in the gerbil.

Contreras PC, Gray NM, Ragan DM, Lanthorn TH.

Life Sci. 1992;51(14):1145-9.

PMID:
1518377
25.
26.

Phencyclidine increased release of beta-endorphin from anterior lobe of the pituitary.

Contreras PC, Jacobson AE, Rice KC, Farah JM Jr.

J Pharmacol Exp Ther. 1991 Sep;258(3):837-41.

PMID:
1653842
27.

(+) 3-[3-hydroxyphenyl-N-(1-propyl) piperidine] selectively differentiates effects of sigma ligands on neurochemical pathways modulated by sigma receptors: evidence for subtypes, in vivo.

Iyengar S, Wood PL, Mick SJ, Dilworth VM, Gray NM, Farah JM, Rao TS, Contreras PC.

Neuropharmacology. 1991 Aug;30(8):915-22.

PMID:
1723511
28.

Clozapine attenuates N-methyl-D-aspartate receptor complex-mediated responses in vivo: tentative evidence for a functional modulation by a noradrenergic mechanism.

Rao TS, Contreras PC, Cler JA, Emmett MR, Mick SJ, Iyengar S, Wood PL.

Neuropharmacology. 1991 Jun;30(6):557-65.

PMID:
1681442
29.

Evaluation of U-50,488H analogs for neuroprotective activity in the gerbil.

Contreras PC, Ragan DM, Bremer ME, Lanthorn TH, Gray NM, Iyengar S, Jacobson AE, Rice KC, de Costa BR.

Brain Res. 1991 Apr 12;546(1):79-82.

PMID:
1649669
31.

Contrasting neurochemical interactions of tiletamine, a potent phencyclidine (PCP) receptor ligand, with the N-methyl-D-aspartate-coupled and -uncoupled PCP recognition sites.

Rao TS, Contreras PC, Cler JA, Mick SJ, Dilworth VM, Iyengar S, Monahan JB, Wood PL.

J Neurochem. 1991 Mar;56(3):890-7.

PMID:
1847186
32.

Immune modifying effects of misoprostol and natural prostaglandins.

Iyengar S, Contreras PC, Mick SJ, Bremer ME, McKearn JP.

Br J Rheumatol. 1991;30 Suppl 2:71-4.

PMID:
1899625
33.

Opipramol, a potent sigma ligand, is an anti-ischemic agent: neurochemical evidence for an interaction with the N-methyl-D-aspartate receptor complex in vivo by cerebellar cGMP measurements.

Rao TS, Cler JA, Mick SJ, Ragan DM, Lanthorn TH, Contreras PC, Iyengar S, Wood PL.

Neuropharmacology. 1990 Dec;29(12):1199-204.

PMID:
1963477
34.

Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivo.

Rao TS, Cler JA, Mick SJ, Dilworth VM, Contreras PC, Iyengar S, Wood PL.

Neuropharmacology. 1990 Dec;29(12):1191-7.

PMID:
1963476
35.

Synthesis and evaluation of N-substituted cis-N-methyl-2-(1-pyrrolidinyl)cyclohexylamines as high affinity sigma receptor ligands. Identification of a new class of highly potent and selective sigma receptor probes.

de Costa BR, Rice KC, Bowen WD, Thurkauf A, Rothman RB, Band L, Jacobson AE, Radesca L, Contreras PC, Gray NM, et al.

J Med Chem. 1990 Nov;33(11):3100-10.

PMID:
2172538
36.

Ifenprodil and SL 82.0715 potently inhibit binding of [3H](+)-3-PPP to sigma binding sites in rat brain.

Contreras PC, Bremer ME, Gray NM.

Neurosci Lett. 1990 Aug 14;116(1-2):190-3.

PMID:
1979666
37.

Sigma receptors modulate both A9 and A10 dopaminergic neurons in the rat brain: functional interaction with NMDA receptors.

Iyengar S, Dilworth VM, Mick SJ, Contreras PC, Monahan JB, Rao TS, Wood PL.

Brain Res. 1990 Aug 6;524(2):322-6.

PMID:
1963339
38.

Inhibition of potassium-evoked release of cholecystokinin from rat caudate-putamen, cerebral cortex and hippocampus incubated in vitro by phencyclidine and related compounds.

Allard LR, Brog JS, Viereck JC, Contreras PC, Jacobson AE, Rice KC, Beinfeld MC.

Brain Res. 1990 Jul 9;522(2):224-6.

PMID:
2171716
39.
40.
41.
42.

H1 antihistamines interact with central sigma receptors.

Gray NM, Contreras PC, Allen SE, Taylor DP.

Life Sci. 1990;47(2):175-80.

PMID:
1975080
43.

Ifenprodil and SL 82.0715 antagonize N-methyl-D-aspartate (NMDA)-coupled glycine receptor responses in vivo.

Rao TS, Cler J, Emmett MR, Mick S, Iyengar S, Contreras PC, Wood PL.

Eur J Pharmacol. 1989 Sep 1;168(1):129-31. No abstract available.

PMID:
2573532
44.

Phencyclidine-like effects of tetrahydroisoquinolines and related compounds.

Gray NM, Cheng BK, Mick SJ, Lair CM, Contreras PC.

J Med Chem. 1989 Jun;32(6):1242-8.

PMID:
2542555
45.

[3H]MK-801 binding in Alzheimer's disease.

Mouradian MM, Contreras PC, Monahan JB, Chase TN.

Neurosci Lett. 1988 Nov 11;93(2-3):225-30.

PMID:
2853845
46.

Synthesis, configuration, and evaluation of two conformationally restrained analogues of phencyclidine.

de Costa BR, George C, Burke TR Jr, Rafferty MF, Contreras PC, Mick SJ, Jacobson AE, Rice KC.

J Med Chem. 1988 Aug;31(8):1571-5.

PMID:
3397994
47.

Glycine modulation of the phencyclidine binding site in mammalian brain.

Thomas JW, Hood WF, Monahan JB, Contreras PC, O'Donohue TL.

Brain Res. 1988 Mar 1;442(2):396-8.

PMID:
2836022
48.

Biochemical and behavioral effects of sigma and PCP ligands.

Contreras PC, Contreras ML, O'Donohue TL, Lair CC.

Synapse. 1988;2(3):240-3.

PMID:
2850629
49.

Selective memory impairment by phencyclidine in rats.

Handelmann GE, Contreras PC, O'Donohue TL.

Eur J Pharmacol. 1987 Aug 4;140(1):69-73.

PMID:
3622624
50.

The N-methyl-D-aspartate antagonist, 2-amino-7-phosphonoheptanoate, produces phencyclidine-like behavioral effects in rats.

Compton RP, Contreras PC, O'Donohue TL, Monahan JB.

Eur J Pharmacol. 1987 Apr 7;136(1):133-4. No abstract available.

PMID:
3297738

Supplemental Content

Loading ...
Support Center